Home » Orthometrix Announces Canadian MDL for Orbasone System
Orthometrix Announces Canadian MDL for Orbasone System
Orthometrix announced at the International Foot and Ankle Congress in Toronto, Ontario, that its new Orbasone Pain Relief System received a medical device license (MDL) from Health Canada and may now be sold in the Canadian market for treatment of chronic plantar fasciitis (foot pain). The Orbasone is manufactured in the U.S. by Kimchuk of Danbury, Conn., and distributed in Canada by Orthometrix.
MENAFN (http://menafn.com/qn_news_story.asp?StoryId=CqOgdqbKbmtmXyJK3ntC)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May